Canadian health care magpie Valeant (NYSE: VRX )
certainly knows how to stay in the spotlight. Investors simply aren't
all that interested in quarterly earnings at a time when the company is
actively trying to ratchet up the pressure on Allergan (NYSE: AGN )
to accept the company's acquisition offer. Valeant continues to look
undervalued as it is likely still in the early to-middle years of a
debt-fueled grab for scale. However, as the pushback from Allergan
shows, not all of the targets Valeant may choose will welcome the
company's efforts at empire-building.
Read the full article here:
Valeant Pharmaceuticals's Earnings Take a Back Seat To Allergan News
No comments:
Post a Comment